Stockholm, Sweden – SciBase Holding AB (STO: SCIB), a leader in artificial intelligence-driven solutions for skin diagnostics, has announced promising results from a recent case study that explores the use of its Nevisense device for monitoring treatment outcomes in patients with atopic dermatitis (AD). The study, conducted by researchers at Koç University in Istanbul, highlights Nevisense’s potential to transform the management of AD, a common and chronic inflammatory skin condition.
Atopic dermatitis, which affects approximately 7% of adults and up to 20% of children worldwide, is marked by compromised skin barrier function and an altered immune response. Traditional treatment methods have largely focused on managing flare-ups, but the new findings suggest that Nevisense, which employs electrical impedance spectroscopy (EIS) technology, could offer a more precise way to track changes in skin barrier integrity and evaluate treatment efficacy.
The case study tracked the progress of an 8-year-old girl with severe AD over a six-month treatment period, during which her skin barrier function was monitored using Nevisense. The patient, who received treatment with dupilumab, a monoclonal antibody targeting the IL-4 and IL-13 pathways, showed significant improvement. Her SCORAD (Scoring Atopic Dermatitis) score dropped from 96 to 37, a notable reduction that correlated strongly with improvements in skin barrier function as measured by Nevisense.
Pia Renaudin, CEO of SciBase, described the findings as a “breakthrough” in dermatology. “This study underscores the critical role of skin barrier function in the management of atopic dermatitis,” Renaudin said. “Nevisense offers a non-invasive, real-time way for healthcare providers to monitor treatment efficacy and improve patient outcomes.”
As atopic dermatitis continues to increase in prevalence globally, there is growing demand for advanced tools to assess and manage the condition. SciBase’s Nevisense, by enabling accurate and non-invasive monitoring of skin barrier integrity, is positioned to play a pivotal role in the future of AD treatment. The results of this case study add to the growing body of evidence supporting the use of Nevisense in clinical settings, paving the way for wider adoption and helping to address the unmet needs of AD patients worldwide.
With increasing awareness of skin barrier dysfunction’s role in AD, SciBase is poised to capitalize on a rapidly expanding market for skin assessment devices, offering healthcare professionals a valuable tool for optimizing patient care in dermatology.
Related topics:
